NEW YORK — By the time patients arrive at the office of Bruce Hirsch, an infectious disease specialist at North Shore University Hospital in Long Island, they’re desperate. Many have diarrhea that strikes up to 20 times a day. They eagerly pay $1,200 out of pocket for the only thing that might make their lives normal again.
Hirsch offers them an orange pill, which they swallow. Underneath the pill’s outer shell are several smaller gel capsules. Inside the smallest capsule is a glycerin-suspended clump of bacteria that’s been extracted from human feces.
“It’s like a Russian doll,” Hirsch told me. “With a surprise in the middle.”
Hirsch is one of just a few dozen specialists in the country who perform fecal transplants—procedures used primarily to treat people who have severe gut infections caused by an overgrowth of a bacteria called Clostridium difficile.
But he’s also part of an even smaller group of practitioners who offer the transplants orally, with a pill regimen that was initially pioneered by Tom Louie, an infectious disease specialist in Calgary, Canada.
Hirsch’s interest in treating C. diff, as it’s sometimes called, was prompted by patients whose lives were completely destroyed—or ended—by their infections.
A few years ago, Hirsch saw a man in his 40s—an otherwise healthy runner who had developed a common respiratory infection. He was prescribed an antibiotic, and three days later he began experiencing severe diarrhea caused by a C. diff infection. Eventually he developed a complication of C. diff known as toxic megacolon, in which the colon swells and, in some patients, ruptures.
“Within 48 hours, he was on the table of an operating room having his colon removed,” Hirsch said. “He went from a healthy, jogging, middle-aged normal guy to an individual who is fated to shit out of his side for the rest of his life into a colostomy bag.”
More than 250,000 Americans each year require hospitalization for C. diff infections, and roughly 14,000 die from it, according to the CDC. In its recent report on drug resistance, the CDC classified C. diff as an “urgent” threat.
C. diff infections are often sparked when a person with an unrelated ailment takes a round of antibiotics, which kill off the gut’s “good” bacteria in the process. But Hirsch said he sees the bacteria even in patients who haven’t used antibiotics recently.
To him, this means C. diff is generating hearty, impossible-to-kill spores that allow it to jump from person to person, including within hospitals.
To make matters worse, certain strains of C. diff have evolved to withstand even the heaviest bombardment by drugs. Until recently, it could be treated with antibiotics, but in the late 1990s, the bug morphed and became much harder to eliminate.
“We knew we had a horrific problem,“ Mark Miller, former head of infectious diseases at the Jewish General Hospital in Montreal and a doctor who helped document C. diff’s transformation, told a Canadian news service. “We knew it was a bad C. diff, a more virulent C. diff.”
Increasingly, doctors are finding that their last remaining weapon is the bacteria from a healthy person’s bowels.
Fecal transplants aren’t a new therapy—the first was performed in 1958—but it’s still a relatively rare procedure because it’s logistically and, well, cognitively unappealing. Only about 20 doctors in the U.S. perform the procedure, and just 500 to 700 patients have received the transplants.
However, the rise of this more tenacious C. diff strain is pushing both patients and doctors to get over their fecal fears. In January, a study in the New England Journal of Medicine found that a far higher percentage of patients infected with C. diff recovered among a group being given an enema containing the stool of a healthy donor than did among those who were treated with antibiotics. Fecal transplants have been shown in that and other studies to cure 90 percent of C. diff infections within a few days.
But the procedure is far from simple. In clinics, they’re usually administered through a colonoscopy-type procedure, which is uncomfortable for sick and elderly patients, or through a tube stuck down the patient’s nose and into the stomach, which only exacerbates the patient’s natural feeling of disgust.
And because so few doctors offer them, some patients have been driven to try fecal transplants at home by themselves, usually by using a relative’s stool. But doing so outside a clinical setting, and without first testing the sample and donor for pathogens, is considered risky.
The first person Hirsch performed a fecal transplant on using the tube method was a 4’10 woman in her late 80s.
“She was very stoic, but it’s an awful experience,” he said.
By contrast, his “crapsules” are a breeze. “It’s a 10-capsule regimen with smiles and hugs from me. It’s a nothing procedure.”
Hirsch can’t meet the current demand for the pills, but with the help of a new biomedical startup, he’s hoping to get them in the hands of more and more patients.
Despite his years in medicine, Hirsch seems perpetually shocked by how poop—the archetypal odious substance—can be so curative. Shit’s inherent nastiness is, it seems, partly what’s been holding it back from curing countless C. diff patients by now.